Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term phase-iii. Found 22 abstracts

no pagination
Colt DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, DiMaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. Journal of the National Comprehensive Cancer Network. 2012 Mar;10(3):366-400.   PMCID: not NIH funded
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L. Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer. Annals of Surgical Oncology. 2012 May;19(5):1508-16.   PMCID: not NIH funded
Giralt SA, Mangan KF, Maziarz RT, Bubalo JS, Beveridge R, Hurd DD, Mendoza FL, Rubenstein EB, DeGroot TJ, Schuster MW. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. Annals of Oncology. 2011 Apr;22(4):939-46.   PMCID: not NIH funded
Blay JY, von Mehren M, Blackstein ME. Perspective on Updated Treatment Guidelines for Patients With Gastrointestinal Stromal Tumors. Cancer. 2010 Nov;116(22):5126-37.   PMCID: NIH funded
Mortimer JE, Barsevick AM, Bennett CL, Berger AM, Cleeland C, DeVader SR, Escalante C, Gilreath J, Hurria A, Mendoza TR, Rugo HS. Studying Cancer-Related Fatigue: Report of the NCCN Scientific Research Committee. Journal of the National Comprehensive Cancer Network. 2010 Dec;8(12):1331-9.   PMCID: not NIH funded
Gold HT, Hall MJ, Blinder V, Schackman BR. Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer. Cancer. 2009 Sep;115(17):3858-67.   PMCID: PMC2853177
Hu W, Ding WJ, Yang HH, Shao MH, Wang BY, Wang JH, Wu SF, Wu SX, Jin LH, Ma CC. Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. Radiotherapy and Oncology. 2009 Dec;93(3):488-91.
Movsas B, Scott C, Watkins-Bruner D. Pretreatment factors significantly influence quality of life in cancer patients: A radiation therapy oncology group (RTOG) analysis. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 2006 Jul;65(3):830-5.
Ozols RF, Bookman MA, Young RC, Du Bois A, Pfisterer J, Reuss A. Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. GYNECOLOGIC ONCOLOGY. 2006 Oct;103(1):1-6.
Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, Byhardt RW, Curran WJ. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. International Journal of Radiation Oncology Biology Physics. 2005 Nov;63(3):667-71.
Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. Journal of Clinical Oncology. 2005 Apr;23(10):2145-54.
Langer CJ. The Lilenbaum article reviewed. ONCOLOGY-NEW YORK. 2004 Sep;18(10):1330-3.
Langer C, Lilenbaum R. Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer. Seminars in Oncology. 2004 Dec 11;31(6):8-15.
Ozols RF, Vermorken JB. Chemotherapy of advanced ovarian cancer: Current status and future directions. Seminars in Oncology. 1997 Feb;24(1):S1-S9.
Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O, Fisher H, Rosenthal J, Witte R, Schinella R, Trump D. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: Flutamide versus diethylstilbestrol. Journal of Clinical Oncology. 1996 Aug;14(8):2250-7.
Ozols RF. Paclitaxel (Taxol(R)) plus carboplatin as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer. 1996 Jan;6:9-12.
Ozols RF. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer. Seminars in Oncology. 1995 Dec;22(6):1-6.
Ozols RF. Current Status of Chemotherapy for Ovarian-Cancer. Seminars in Oncology. 1995 Oct;22(5):61-6.
Ozols RF. Carboplatin and Paclitaxel in Ovarian-Cancer. Seminars in Oncology. 1995 Jun;22(3):78-83.
Ozols RF. Carboplatin and Paclitaxel (Taxol(R)) for the Treatment of Advanced Ovarian-Cancer. International Journal of Gynecological Cancer. 1994 Nov;4:13-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term phase-iii

phase-iii cisplatin cyclophosphamide chemotherapy carboplatin cancer randomized-trial paclitaxel radiotherapy quality-of-life randomized trial Oncology taxol gynecologic-oncology-group therapy trial ovarian cancer multicenter elderly-patients survival trials double-blind oncology-group iii randomized-trial carcinoma clinical-trials surgical excision Nuclear Medicine & Medical Imaging Radiology methylphenidate factors to fatigue induction concurrent chemotherapy quality of life placebo-controlled trial chemoradiotherapy breast-cancer term follow-up eortc qlq-c30 lymph node dissection induced emesis myeloma gemcitabine plus plus gemcitabine cyproterone-acetate palonosetron fluorouracil failure plus chemotherapy-induced nausea tyrosine-kinase inhibitor recombinant interleukin-2 therapy experience treatment 5-fluorouracil guideline NCCN Guidelines interruptions 1993 n jkl-journal of dermatologic surgery and oncology-v19-p985 Chemoradiotherapy dexamethasone pretreatment factors metastatic metastases consensus conference single-agent carboplatin skin radiation therapy intensification NCCN Clinical Practice Guidelines surgical adjuvant breast 5-ht3 receptor stage-iii ovarian intergroup trial moderately emetogenic ugt1a1-asterisk-28 genotype radiation-therapy impaired renal-function positron-emission-tomography lymphoma pathology 1st-line treatment Nasopharyngeal carcinoma fatigue assessment Locally advanced isolated limb perfusion ondansetron c-kit neck medroxyprogesterone acetate stage-iii melanoma cell lung-cancer dosage metaanalysis pain questionnaire vinorelbine susceptibility gene interferon sentinel lymph node college doxorubicin folfiri non-small-cell lung carcinoma cooperative-oncology-group primary cutaneous melanoma adjuvant therapy endocrine therapy high-dose melphalan supportive care imatinib mesylate depression population margin thoracic radiotherapy cyclophosphamide chemotherapy chemoradiation drug development nonsteroidal antiandrogen expert panel gist neutropenia randomized etoposide high-risk melanoma intraindividual changes multicenter trial favorable patients socioeconomic-status impact stromal gastrointestinal-tumors-imatinib-practice guideline-protein tyrosine-kinases-sunitinib pharmacokinetics preoperative chemotherapy targeted therapy melanoma pathological complete response surgical-management Cancer-related fatigue continuous-infusion nausea term-follow-up head Obstetrics & Gynecology UGT1A1 genotype testing-irinotecan-cost-effectiveness analysis-colorectal cancer clinical-oncology malignant-melanoma dose imatinib lymph-node biopsy recommendations infusion esophagitis scores
Last updated on Monday, July 06, 2020